NCT05813327 2026-03-17
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Washington University School of Medicine
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT06085729 2026-02-27
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
M.D. Anderson Cancer Center
Phase 1/2 Suspended
NCT05616624 2026-02-04
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT03970447 2025-09-09
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT03922880 2025-05-15
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT06034977 2023-09-13
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT04965714 2023-02-16
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00520299 2022-10-25
Study of ADI-PEG 20 in Patients With Advanced Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03498222 2020-02-25
iTRAP
Queen Mary University of London
Phase 1 Withdrawn
NCT00450372 2017-02-08
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
University of Miami
Phase 2 Completed
NCT01279967 2014-11-20
ADAM
Barts & The London NHS Trust
Phase 2 Unknown